Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury

Vergouwen, Mervyn D.I.; Roos, Yvo B.W.E.M.; Kamphuisen, Pieter Willem

doi:10.1097/mcc.0b013e3282f57540

Cited by 19 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administered within 48 h of admission, and continued to discharge] is associated with a low frequency of intracranial haemorrhage (1.1%). These results are consistent with the findings of previous similar studies [42][43][44][45][46].…”

Section: ããsupporting

confidence: 96%

Low-molecular-weight heparin for thromboprophylaxis

Camporese

Bernardi²

2009

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Low-molecular-weight heparins are expanding their application, but progressively they will be replaced by other new antithrombotics for the prophylaxis of venous thromboembolism. Surgical patients undergo a more concerted approach to thromboprophylaxis than medical patients. Future research should aim at improving prophylaxis in the latter setting in order to significantly reduce the rate of venous thromboembolic events.

show abstract

Section: ããsupporting

confidence: 96%

Low-molecular-weight heparin for thromboprophylaxis

Camporese

Bernardi²

2009

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…VTE is a common complication in patients with acute SCI [83] with its overall incidence ranging from 18 to 100% [84,85] within the first 12 weeks, and with the highest risk of occurrence in the first 2 weeks [86,87]. Rarely do these events occur within the first 3 days after injury.…”

Section: Spinal Cord Injury (Sci)mentioning

confidence: 99%

Prophylaxis for Venous Thrombo-Embolism in Neurocritical Care: A Critical Appraisal

2009

View full text Add to dashboard Cite

Venous thrombo-embolism (VTE) is frequently encountered in critically ill neurological and neurosurgical patients admitted to intensive care units. This patient population includes those with brain neoplasm, intracranial hemorrhage, ischemic stroke, subarachnoid hemorrhage, pre- and post-operative patients undergoing neurosurgical procedures and those with traumatic brain injury, and acute spinal cord injury (SCI). There is a wide variability in clinical practice for thromboprophylaxis in these patients, in part due to paucity of data based on randomized clinical trials. Here, we review the current literature on the incidence of VTE in the critically ill neurological and neurosurgical patients as well as appraise available data to support particular practice paradigms for specific subsets of these patients. Data synthesis was conducted via search of Medline, Cochrane databases, and manual review of article bibliographies. Critically ill neurological and neurosurgical patients have higher susceptibility to VTE. Intermittent compression devices with or without anti-thrombotics is generally the method of choice for thromboprophylaxis. Low molecular weight heparin is the method of choice in certain patient subgroups such as those with SCI and ischemic stroke. Inferior vena cava filters may play a role in thromboprophylaxis in selected cases. Without clear guidelines that can be universally applied to this diverse group of patients, prophylaxis for VTE should be tailored to the individual patient with cautious assessment of benefits versus risks. There is a need for higher level evidence to guide VTE prophylaxis in certain subgroups of this patient population.

show abstract

“…DVT prophylaxis in patients with intracranial hemorrhage (ICH) from any etiology is controversial. The risk of thrombolic events is high in neurological patients, but when ICH is present, anticoagulation may be contraindicated [10,11]. IVC filters can be placed but it is not clear that these devices prevent pulmonary embolus [12,13].…”

Section: Insights From An Experienced Tbi Researcher (Claudia S Robementioning

confidence: 99%

Research Priorities in Neurocritical Care

et al. 2011

View full text Add to dashboard Cite

This summary of the last session of the First Neurocritical Care Research Conference reviews the discussions about research priorities in neurocritical care. The first presentation reviewed current projects funded by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health and potential models to follow including an independent Neurocritical Care Network or the creation of such a network with the goal of collaborating with already existing ones. Experienced neurointensivists then presented their views on the most common and important research questions that need to be answered and investigated in the field. Finally, utility of clinical registries was discussed emphasizing their importance as hypothesis generators. During the group discussion, interests in comparative effectiveness research, the use of physiological endpoints from monitoring and alternate trial design were expressed.

show abstract

Venous thromboembolism prophylaxis and treatment in patients with acute stroke and traumatic brain injury

Abstract: Adequate prevention of venous thromboembolism with intermittent pneumatic compression or pharmacological prophylaxis is important. The best treatment of venous thromboembolism remains unclear. In case of pulmonary embolism, more aggressive treatment is warranted.

Cited by 19 publications

References 53 publications

Low-molecular-weight heparin for thromboprophylaxis

Low-molecular-weight heparin for thromboprophylaxis

Prophylaxis for Venous Thrombo-Embolism in Neurocritical Care: A Critical Appraisal

Research Priorities in Neurocritical Care

Contact Info

Product

Resources

About